158 related articles for article (PubMed ID: 15059137)
1. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Khan SB; Maududi T; Barton K; Ayers J; Alkan S
Br J Haematol; 2004 Apr; 125(2):156-61. PubMed ID: 15059137
[TBL] [Abstract][Full Text] [Related]
2. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
4. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
5. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
[TBL] [Abstract][Full Text] [Related]
6. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
10. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
11. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
[TBL] [Abstract][Full Text] [Related]
12. Expression of BAX in plasma cell dyscrasias.
Renner S; Weisz J; Krajewski S; Krajewska M; Reed JC; Lichtenstein A
Clin Cancer Res; 2000 Jun; 6(6):2371-80. PubMed ID: 10873089
[TBL] [Abstract][Full Text] [Related]
13. Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells.
Mizuno R; Oya M; Hara S; Matsumoto M; Horiguchi A; Ohigashi T; Marumo K; Murai M
Oncol Rep; 2005 Sep; 14(3):639-44. PubMed ID: 16077967
[TBL] [Abstract][Full Text] [Related]
14. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.
Hartlapp I; Pallasch C; Weibert G; Kemkers A; Hummel M; Re D
Leuk Res; 2009 Jul; 33(7):929-36. PubMed ID: 19233470
[TBL] [Abstract][Full Text] [Related]
15. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro].
Zhang H; Lü JJ; Gao QZ; Zhang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):382-5. PubMed ID: 16638347
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells.
Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
Anticancer Drugs; 2007 Apr; 18(4):405-10. PubMed ID: 17351392
[TBL] [Abstract][Full Text] [Related]
17. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1 mediates cytokine deprivation induced apoptosis of human myeloma cell line XG-7.
Song L; Li Y; Sun Y; Shen B
Chin Med J (Engl); 2002 Aug; 115(8):1241-3. PubMed ID: 12215301
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
[TBL] [Abstract][Full Text] [Related]
20. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
